Proton Therapy for Low and Intermediate Risk Prostate Cancer
NCT ID: NCT00693238
Last Updated: 2023-09-18
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
228 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-04-30
Study Completion Date
2022-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer
NCT01368055
Prostate Cancer
COMPLETED
NA
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
NCT03624660
Adenocarcinoma of the Prostate
ACTIVE_NOT_RECRUITING
NA
Hypofractionated Proton Beam Therapy for Localized Prostate Cancer
NCT01950351
Stage I Prostate Adenocarcinoma AJCC v7
Stage II Prostate Adenocarcinoma AJCC v7
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Internal Radiation Therapy in Treating Patients With Prostate Cancer
NCT00573833
Prostate Cancer
COMPLETED
NA
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
NCT01352429
Prostate Adenocarcinoma
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Low Risk - Total of 70 Gy/CGE over 28 treatments
Intermediate Risk - Total of 72.5 Gy/CGE over 29 treatments
Intermediate Risk - Total of 72.5 Gy/CGE over 29 treatments
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Prostate Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Risk Proton Radiation
70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
Group Type
EXPERIMENTAL
Low Risk Proton Radiation
Intervention Type
RADIATION
Intermediate Risk Proton Radiation
72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
Group Type
EXPERIMENTAL
Intermediate Risk Proton Radiation
Intervention Type
RADIATION
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Risk Proton Radiation
Intervention Type
RADIATION
Intermediate Risk Proton Radiation
Intervention Type
RADIATION
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prostate cancer.
* Gleason score 2-7.
* PSA ≤ 20 ng/ml.
* Gleason score 2-7.
* PSA ≤ 20 ng/ml.
Exclusion Criteria
* Previous prostate cancer surgery or pelvic radiation.
* Prior or current chemotherapy for prostate cancer.
* Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum.
* History of proximal urethral stricture requiring dilatation.
* History of hip replacement.
* Diabetes requiring medication.
* Prior intrapelvic surgery.
* Current and continuing anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox).
* On Flomax (Tamsulosin), Hytrin (Terazosin) or Cardura (Doxazosin), Uroxatral (alfuzosin HCl).
* Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.
* Prior or current chemotherapy for prostate cancer.
* Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum.
* History of proximal urethral stricture requiring dilatation.
* History of hip replacement.
* Diabetes requiring medication.
* Prior intrapelvic surgery.
* Current and continuing anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox).
* On Flomax (Tamsulosin), Hytrin (Terazosin) or Cardura (Doxazosin), Uroxatral (alfuzosin HCl).
* Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.
Minimum Eligible Age
18 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Randal H Henderson, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida Proton Therapy Institute
Jacksonville, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer. Cancer J. 2005 May-Jun;11(3):234-40. doi: 10.1097/00130404-200505000-00010.
Reference Type
BACKGROUND
American Cancer Society. 2007. Ref Type: Electronic Citation
Reference Type
BACKGROUND
Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002 Jan;167(1):112-6.
Reference Type
BACKGROUND
Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002 Feb;167(2 Pt 1):528-34. doi: 10.1016/S0022-5347(01)69079-7.
Reference Type
BACKGROUND
Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. doi: 10.1016/j.ijrobp.2004.08.014.
Reference Type
BACKGROUND
Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brabbins DS, Chen PY, Vicini FA. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 2000 Aug;18(15):2869-80. doi: 10.1200/JCO.2000.18.15.2869.
Reference Type
BACKGROUND
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-74. doi: 10.1001/jama.280.11.969.
Reference Type
BACKGROUND
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. 12-12-0003. 9-9-0005. Ref Type: Electronic Citation
Reference Type
BACKGROUND
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):380-5. doi: 10.1016/j.ijrobp.2003.10.059.
Reference Type
BACKGROUND
Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31. doi: 10.1016/j.ijrobp.2004.12.053.
Reference Type
BACKGROUND
Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):609-15. doi: 10.1016/s0360-3016(00)00578-2.
Reference Type
BACKGROUND
Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Zafar Jafri S, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):406-17. doi: 10.1016/j.ijrobp.2003.10.017.
Reference Type
BACKGROUND
Padhani AR, Khoo VS, Suckling J, Husband JE, Leach MO, Dearnaley DP. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33. doi: 10.1016/s0360-3016(99)00040-1.
Reference Type
BACKGROUND
Litzenberg D, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK, Balter JM. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):699-703. doi: 10.1016/s0360-3016(01)02654-2.
Reference Type
BACKGROUND
Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, Levine L. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53. doi: 10.1016/j.ijrobp.2005.12.033. Epub 2006 Mar 20.
Reference Type
BACKGROUND
Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9. doi: 10.1016/j.ijrobp.2004.12.017.
Reference Type
BACKGROUND
Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052.
Reference Type
BACKGROUND
Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005 Feb 14;92(3):488-98. doi: 10.1038/sj.bjc.6602301.
Reference Type
BACKGROUND
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105. doi: 10.1016/s0360-3016(02)02829-8.
Reference Type
BACKGROUND
Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005 Feb 20;23(6):1192-9. doi: 10.1200/JCO.2005.06.154.
Reference Type
BACKGROUND
Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12. doi: 10.1016/0360-3016(95)00063-5.
Reference Type
BACKGROUND
Vargas, C, Martinez, A, and Boike, T. Long term survival benefit of a prospective dose escalation trial using high dose rate (HDR) brachytherapy boost. Int.J.Radiat.Oncol.Biol.Phys.2005. Ref Type: Abstract
Reference Type
BACKGROUND
Vargas C, Martinez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis. 2006;9(3):245-53. doi: 10.1038/sj.pcan.4500882. Epub 2006 Jun 20.
Reference Type
BACKGROUND
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. doi: 10.1001/jama.294.10.1233.
Reference Type
BACKGROUND
Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):988-93. doi: 10.1016/s0360-3016(01)01730-8.
Reference Type
BACKGROUND
Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):904-12. doi: 10.1016/s0360-3016(02)02836-5.
Reference Type
BACKGROUND
Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8. doi: 10.1016/j.ijrobp.2005.05.054. Epub 2005 Sep 19.
Reference Type
BACKGROUND
Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):348-52. doi: 10.1016/j.ijrobp.2003.10.011.
Reference Type
BACKGROUND
Henderson RH, Bryant C, Hoppe BS, Nichols RC, Mendenhall WM, Flampouri S, Su Z, Li Z, Morris CG, Mendenhall NP. Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncol. 2017 Jul;56(7):963-970. doi: 10.1080/0284186X.2017.1287946. Epub 2017 Feb 22.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.floridaproton.org/about-us/contact-us
Contact the University of Florida Proton Therapy Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB201701653
Identifier Type: OTHER
Identifier Source: secondary_id
UFJ 2008-022
Identifier Type: OTHER
Identifier Source: secondary_id
UFPTI 0702-PR04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Radiotherapy for Oligometastatic Prostate Cancer
NCT01859221
COMPLETED
NA
Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
NCT01859689
WITHDRAWN
PHASE2
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT01492972
RECRUITING
PHASE3
Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time
NCT01423474
COMPLETED
NA
Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
NCT02280356
COMPLETED
PHASE2
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
NCT03388619
COMPLETED
PHASE1
Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate
NCT00585962
COMPLETED
PHASE2
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
NCT00091390
COMPLETED
PHASE2
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
NCT05313815
RECRUITING
NA
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
NCT00002602
COMPLETED
PHASE1/PHASE2
Semen Analysis After Proton Therapy for Prostate Cancer
NCT01072513
COMPLETED
NA
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT03987386
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
NCT00002703
COMPLETED
PHASE3
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
NCT00547339
COMPLETED
PHASE1/PHASE2
Radiation Therapy in Treating Patients With Prostate Cancer
NCT01434290
COMPLETED
PHASE2
A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer
NCT04147806
ACTIVE_NOT_RECRUITING
PHASE2
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
NCT00831623
COMPLETED
NA
Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy
NCT02597894
WITHDRAWN
NA
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
NCT00002889
COMPLETED
PHASE2
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer
NCT01505075
UNKNOWN
PHASE1/PHASE2
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT00969111
RECRUITING
NA
Radiation Therapy in Treating Patients With Prostate Cancer
NCT00002480
COMPLETED
PHASE1
Radiation Therapy in Treating Patients With Prostate Cancer
NCT00003290
COMPLETED
PHASE3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
NCT03561220
ACTIVE_NOT_RECRUITING
NA
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
NCT00331773
COMPLETED
PHASE3